



Pharmaids Pharmaceuticals Limited

Date: 11.11.2025

To
The Corporate Relation Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

Dear Sir / Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Subject: Outcome of Board Meeting held on November 11, 2025

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our intimation dated November 06, 2025 regarding the Notice for the Board Meeting, the Board of Directors of the Company in their Meeting held today i.e., Tuesday, November 11, 2025, have, inter alia considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors for the quarter and half year ended September 30, 2025.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, a copy of results along with Limited Review Report thereon is enclosed herewith.

The Financial Results are also available on the website of the Company at www.pharmaids.com and on the website of BSE www.bseindia.com

The Board Meeting commenced at 04:20 P.M. and concluded at 04:50 P.M.

Kindly take the same on your record and oblige.

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance Officer)

Independent Auditor's Review Report on unaudited quarterly standalone financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


To,
The Board of Directors of
Pharmaids Pharmaceuticals Limited

We have reviewed the accompanying statement of Standalone Unaudited financial results of Pharmaids Pharmaceuticals Limited for the quarter and half year ended 30th September 2025 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Our conclusion is not modified in respect of this matter.

For PPKG & Co.
Chartered Accountants
(Firm's Registration No. 009655S)


Girdhari Lal Toshniwal
(Partner)
(M.No- 205140)
UDIN: 25205140BMOPHK7922



Place: Hyderabad
Date: 11th November 2025

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year ended 30th September, 2025

| Particulars | All figures in Rs. Lacs unless otherwise specified | | | | | |
|---|--|-------------------------------|-------------------------------|---------------------------------|---------------------------------|----------------------------|
| | Quarter ended Sep 30, 2025 | Quarter ended Jun 30, 2025 | Quarter ended Sep 30, 2024 | Half Year ended Sep 30, 2025 | Half Year ended Sep 30, 2024 | Year ended Mar 31, 2025 |
| | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| Income | | | | | | |
| Revenue from operations | 596.55 | 111.53 | 83.40 | 708.08 | 100.05 | 234.09 |
| Other income | 19.07 | 34.72 | 0.51 | 53.79 | 0.82 | 101.89 |
| Total income | 615.61 | 146.25 | 83.91 | 761.86 | 100.87 | 335.98 |
| Expenses | | | | | | |
| Cost of materials consumed | 928.75 | 57.48 | - | 986.22 | - | 3.01 |
| Purchase of stock-in-trade | - | 39.60 | 61.50 | 39.60 | 83.20 | 186.55 |
| Changes in inventories of finished goods and work-in-progress | (276.78) | 9.30 | 4.10 | (267.48) | (2.60) | 11.43 |
| Employee benefits expense | 159.86 | 139.74 | 71.71 | 299.61 | 145.67 | 341.82 |
| Finance costs | 101.95 | 111.06 | 1.27 | 213.02 | 2.55 | 214.91 |
| Depreciation and amortisation expense | 5.65 | 5.10 | 4.96 | 10.75 | 9.74 | 19.95 |
| Other expenses | 242.61 | 353.13 | 59.00 | 595.74 | 158.40 | 417.03 |
| Total expenses | 1,162.05 | 715.41 | 202.54 | 1,877.46 | 396.96 | 1,194.68 |
| Profit/ (Loss) before exceptional items and tax | (546.43) | (569.17) | (118.63) | (1,115.60) | (296.09) | (858.70) |
| Exceptional items | 313.05 | 0.03 | - | 313.08 | - | - |
| Profit/ (Loss) before tax | (233.38) | (569.13) | (118.63) | (802.51) | (296.09) | (858.70) |
| Tax expense | | | | | | |
| Current tax | - | - | - | - | - | - |
| Deferred tax | (68.15) | (132.83) | (17.97) | (200.98) | (33.09) | (130.78) |
| Total Tax Expense | (68.15) | (132.83) | (17.97) | (200.98) | (33.09) | (130.78) |
| Profit/ (Loss) for the year | (165.23) | (436.30) | (100.66) | (601.53) | (263.00) | (727.92) |
| Other comprehensive income | | | | | | |



PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year ended 30th September, 2025

All figures in Rs. Lacs unless otherwise specified


| Particulars | Quarter ended Sep 30, 2025 (Unaudited) | Quarter ended Jun 30, 2025 (Unaudited) | Quarter ended Sep 30, 2024 (Unaudited) | Half Year ended Sep 30, 2025 (Unaudited) | Half Year ended Sep 30, 2024 (Unaudited) | Year ended Mar 31, 2025 (Audited) |
|---|--|--|--|--|--|---|
| (i) Items that will not be reclassified subsequently to profit or loss | | | | | | |
| Re-measurement on defined benefit plans and equity instruments | 0.24 | 0.24 | - | 0.48 | - | 0.95 |
| Income tax effect | (0.06) | (0.06) | - | (0.12) | - | (0.25) |
| (ii) Items that will be reclassified subsequently to profit or loss | | | | | | |
| Effective portion of gains/(losses) on hedging instrument in cash flow hedges | - | - | - | - | - | - |
| Income tax effect | - | - | - | - | - | - |
| Other comprehensive income for the year, net of taxes | 0.18 | 0.18 | - | 0.35 | - | 0.70 |
| Total comprehensive income for the year | (165.06) | (436.12) | (100.66) | (601.18) | (263.00) | (727.22) |
| Paid-up Equity share capital (Face value Rs. 10/- per share) | 3,526.78 | 3,526.78 | 3,526.78 | 3,526.78 | 3,526.78 | 3,526.78 |
| Other Equity (excluding revaluation reserve) | | | | | | 2,852.10 |
| Earnings per equity share | | | | | | |
| Basic (in Rs) | (0.47) | (1.24) | (0.29) | (1.70) | (0.75) | (2.06) |
| Diluted (in Rs) | (0.47) | (1.24) | (0.29) | (1.70) | (0.75) | (2.06) |

Place: Bengaluru

Date: 11-11-2025

**By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited**

Venu Madhava Kaparthy
Whole Time Director
DIN : 00021699



PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Notes to Accounts:

1. The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its respective meetings held on November 11, 2025.
2. The unaudited standalone financials results of the company have been prepared in accordance with the Ind AS as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act 2013 read with rule 3 of the Companies (Indian Accounting Standard) Rules 2015 (as amended) and in accordance with the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The company operates in a single segment of providing Contract Research and Manufacturing Services.
4. The figures for the previous periods have been regrouped / reclassified wherever considered necessary.
5. The company has disinvested its entire 66.5% partnership stake in Anugraha Chemicals, following shareholders' approval obtained through a Postal Ballot Notice in accordance with the Companies Act, 2013 and SEBI Listing Regulations. Therefore, Anugraha Chemicals is no longer a subsidiary of the company.

Place: Bengaluru

Date: 11-11-2025

**By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited**


Venu Madhava Kaparthy
Whole Time Director
DIN : 00021699



PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Standalone Balance Sheet

All figures in Rs. Lacs unless otherwise specified

| Particulars | As at 30 Sep 2025 (Unaudited) | As at 31 March 2025 (Audited) |
|--|-------------------------------------|-------------------------------------|
| | | |
| ASSETS | | |
| Non-current assets | | |
| Property, plant and equipment | 792.92 | 2,390.10 |
| Capital work-in-progress | 318.00 | 350.54 |
| Right-of-use assets | 21.22 | 27.92 |
| Other intangible assets | | |
| (i) Investments | 5,254.48 | 5,261.13 |
| (ii) Other financial assets | 555.45 | 1,627.29 |
| Deferred tax assets (net) | 715.83 | 514.98 |
| Other non-current assets | 26.27 | 32.00 |
| Total non-current assets | 7,684.18 | 10,203.97 |
| Current assets | | |
| Inventories | 371.19 | 976.52 |
| Financial assets | | |
| (ii) Cash and cash equivalents | 8.71 | 46.93 |
| Other current assets | 154.51 | 221.86 |
| Total current assets | 2,038.38 | 1,267.76 |
| TOTAL ASSETS | 9,722.55 | 11,471.72 |
| EQUITY AND LIABILITIES | | |
| Equity | | |
| Equity share capital | 3,526.78 | 3,526.78 |
| Other equity | 2,250.91 | 2,852.10 |
| Total equity | 5,777.70 | 6,378.88 |
| Liabilities | | |
| Non-current liabilities | | |
| Financial liabilities | | |
| (i) Borrowings | 1,817.15 | 3,543.00 |
| (ii) Lease liabilities | 8.55 | 15.68 |
| Current liabilities | | |
| Financial liabilities | | |
| (i) Trade payables | | |
| total outstanding dues of micro and small enterprises | 6.62 | - |
| total outstanding dues of creditors other than micro and small enterprises | 1,160.53 | 1,137.80 |
| (ii) Other financial liabilities | 547.12 | 249.04 |
| Provisions | 0.04 | 0.06 |
| Other current liabilities | 381.30 | 120.90 |
| Total Current Liabilities | 2,111.44 | 1,523.25 |
| TOTAL EQUITY AND LIABILITIES | 9,722.55 | 11,471.72 |

Place: Bengaluru

Date: 11-11-2025

By the order of the Board of Directors


Venu Madhava Kaparthi
 Whole Time Director
 DIN: 00021699



PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Standalone Statement of Cash Flows

All figures in Rs. Lacs unless otherwise specified

| Particulars | Period ended 30 Sep 2025 (Unaudited) | Period ended 30 Sep 2024 (Unaudited) |
|---|--|--|
| | | |
| Cash flows from operating activities | | |
| Net Profit Before Tax | (802.51) | (296.09) |
| <u>Adjustments to reconcile profit before tax to net cash flows:</u> | | |
| Depreciation | 10.75 | 9.74 |
| Interest income | (53.79) | (0.82) |
| Finance Cost | 213.02 | 2.55 |
| Provision for gratuity | 3.05 | |
| Gain on sale of assets | (316.25) | |
| Share of loss in partnership firm | 61.35 | 117.03 |
| Loss on exit from subsidiary | 2.45 | |
| Other Non cash adjustments | (47.01) | |
| <u>Adjustments for changes in working capital:</u> | | |
| (Increase)/decrease in inventories | 605.33 | (2.60) |
| (Increase)/decrease in trade receivables | (657.42) | (75.23) |
| (Increase)/decrease in other financial assets | 104.68 | 7.53 |
| (Increase)/decrease in other current assets | 73.07 | 4.92 |
| Increase/(decrease) in trade payables | 29.34 | 45.46 |
| Increase/(decrease) in other financial liabilities | 116.47 | 7.17 |
| Increase/(decrease) in other provisions | (5.78) | (0.23) |
| Increase/(decrease) in other current liabilities | 260.40 | (5.23) |
| Cash generated from/(used in) operations | (402.85) | (185.79) |
| Income tax paid | | |
| Net cash flows generated from/(used in) operating activities (A) | (402.85) | (185.79) |
| Cash flows from investing activities | | |
| Purchase of property, plant and equipment incl. CWIP | (14.02) | (9.11) |
| Sale of property, plant and equipment | 1,955.94 | |
| Interest on loan and bank deposits | 46.35 | 0.19 |
| Investment in Fixed Deposit | (11.53) | - |
| Investment in subsidiaries/ associates | - | (33.50) |
| Consideration received on Exit from subsidiary | 206.65 | - |
| Loans given | (54.75) | (91.00) |
| Net cash flow generated from/(used in) investing activities (B) | 2,128.64 | (133.42) |
| Cash flow from Financing activities | | |
| Repayment of borrowing | (2,185.85) | 166.00 |
| Proceeds from borrowing | 460.00 | - |
| Interest on loan | (29.54) | - |
| Repayment of lease liabilities | (8.61) | (8.14) |
| Net cash flow generated from/(used in) financing activities (C) | (1,764.01) | 157.86 |
| Net increase in cash and cash equivalents (A+B+C) | (38.21) | (161.35) |
| Cash and cash equivalents at the beginning of the year | 46.93 | 245.93 |
| Cash and cash equivalents at the end of the year | 8.71 | 84.58 |
| Cash and cash equivalents comprise | | |
| Cash on hand | 0.61 | 0.65 |
| Balances with banks in current & deposit accounts | 8.10 | 83.93 |
| Total cash and cash equivalents | 8.71 | 84.58 |

Place: Bengaluru

Date: 11-11-2025

By the order of the Board of Directors

Venu Madhava Kaparthy

Whole Time Director

DIN: 00021699



Independent Auditor's Review Report on unaudited quarterly consolidated financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors,

Pharmaids Pharmaceuticals Limited (Holding Company)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Pharmaids Pharmaceuticals Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its subsidiaries for the quarter and half year ended 30th September 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.


4. The Statement includes the results of the following entities:
 - i. Adita Bio Sys Private Limited
 - ii. Siri Labvivo Diet Private Limited (step down subsidiary)
 - iii. Spring labs (step down subsidiary)



5. We draw attention to Note No. 5 of the Statement, which describes that the Company has exited from its partnership firm Anugraha Chemicals, during the quarter ended 30th September 2025, pursuant to a resolution passed by the Board of Directors. The consideration amount of ₹1050 Lakhs was agreed towards settlement of its capital and share of profits/loss in the said firm. Based on the information and explanations provided to us, this transaction has been appropriately recognized and disclosed in the accompanying financial results. Our conclusion is not modified in respect of this matter.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the interim financial results of 1 subsidiary and 2 step down subsidiaries included in the consolidated unaudited financial results, whose interim financial statements / financial information / financial results reflect total revenues of Rs.553.56 Lakhs, total net (loss) after tax of Rs. (134.92) Lakhs and total comprehensive (loss) of Rs. (131.45) Lakhs for the quarter and half year ended 30th September 2025, respectively and cash flows (net) of Rs. 2.76 Lakhs for the period ended 30th September 2025 as considered in the consolidated unaudited financial results.

These interim financial statements / financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Consolidated Financial Statement is not modified in respect of the above matters.

For PPKG & Co.
Chartered Accountants
(Firm's Registration No. 0096558)

Girdhari Lal Toshniwal
(Partner)
(M.No- 205140)
UDIN: 25205140BMOPHL5380



Place: Hyderabad
Date: 11th November 2025

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979


Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Half Year ended 30th September, 2025

All figures in Rs. Lacs unless otherwise specified

| Particulars | Quarter ended Sep 30, 2025 (Unaudited) | Quarter ended Jun 30, 2025 (Unaudited) | Quarter ended Sep 30, 2024 (Unaudited) | Half Year ended Sep 30, 2025 (Unaudited) | Half Year ended Sep 30, 2024 (Unaudited) | Year ended Mar 31, 2025 (Audited) |
|---|--|--|--|--|--|---|
| Income | | | | | | |
| Revenue from operations | 860.50 | 666.36 | 523.93 | 1,526.86 | 997.00 | 1,944.74 |
| Other income | 22.15 | 4.01 | 1.32 | 26.16 | 2.27 | 10.40 |
| Total income | 882.65 | 670.37 | 525.25 | 1,553.02 | 999.27 | 1,955.14 |
| Expenses | | | | | | |
| Cost of materials consumed | 983.97 | 243.39 | 244.02 | 1,227.36 | 546.15 | 932.44 |
| Purchase of stock-in-trade | 45.18 | 108.06 | 110.35 | 153.24 | 143.82 | 314.06 |
| Changes in inventories of finished goods and work-in-progress | (274.10) | (0.88) | 4.66 | (274.99) | 72.88 | 36.33 |
| Employee benefits expense | 318.09 | 418.76 | 287.06 | 736.85 | 586.26 | 1,316.24 |
| Finance costs | 107.66 | 119.55 | 33.46 | 227.20 | 59.58 | 208.76 |
| Depreciation and amortisation expense | 46.75 | 60.62 | 61.48 | 107.37 | 118.07 | 244.02 |
| Other expenses | 319.60 | 434.25 | 118.65 | 753.85 | 244.37 | 621.44 |
| Total expenses | 1,547.15 | 1,383.74 | 859.68 | 2,930.89 | 1,771.15 | 3,673.29 |
| Profit/ (Loss) before exceptional items and tax | (664.50) | (713.37) | (334.43) | (1,377.87) | (771.88) | (1,718.15) |
| Exceptional items | 298.78 | 0.03 | 6.95 | 298.82 | (14.58) | (9.78) |
| Profit/ (Loss) before tax | (365.72) | (713.33) | (327.48) | (1,079.05) | (786.46) | (1,727.93) |
| Tax expense | | | | | | |
| Current tax | - | - | - | - | - | - |
| Tax paid for earlier years | - | - | 0.37 | - | 0.37 | 6.29 |
| Deferred tax | (112.88) | (185.55) | (100.41) | (298.44) | (218.07) | (383.70) |
| Total Tax Expense | (112.88) | (185.55) | (100.03) | (298.44) | (217.69) | (377.41) |
| Profit/ (Loss) for the year | (252.83) | (527.78) | (227.44) | (780.61) | (568.76) | (1,350.51) |
| Other comprehensive income | | | | | | |
| (i) Items that will not be reclassified subsequently to profit or loss | | | | | | |
| Re-measurement on defined benefit plans and equity instruments | 2.58 | 1.11 | - | 3.69 | - | 2.19 |
| Income tax effect | (0.67) | (0.21) | - | (0.88) | - | (0.15) |
| (ii) Items that will be reclassified subsequently to profit or loss | | | | | | |
| Effective portion of gains/(losses) on hedging instrument in cash flow hedges | - | - | - | - | - | - |
| Income tax effect | - | - | - | - | - | - |
| Other comprehensive income for the year, net of taxes | 1.91 | 0.90 | - | 2.81 | - | 2.05 |
| Total comprehensive income for the year | (250.92) | (526.88) | (227.44) | (777.81) | (568.76) | (1,348.47) |



PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com


Statement of Unaudited Consolidated Financial Results for the Quarter and Half Year ended 30th September, 2025

All figures in Rs. Lacs unless otherwise specified

| Particulars | Quarter ended Sep 30, 2025 (Unaudited) | Quarter ended Jun 30, 2025 (Unaudited) | Quarter ended Sep 30, 2024 (Unaudited) | Half Year ended Sep 30, 2025 (Unaudited) | Half Year ended Sep 30, 2024 (Unaudited) | Year ended Mar 31, 2025 (Audited) |
|---|--|--|--|--|--|---|
| Profit/ (Loss) attributable to: | | | | | | |
| Equity holders of the Holding company | (248.04) | (491.39) | (222.00) | (739.44) | (490.44) | (1,077.66) |
| Non-controlling interest | (4.79) | (36.39) | (34.30) | (41.18) | (78.32) | (272.85) |
| Profit/ (Loss) for the year | (252.83) | (527.78) | (256.31) | (780.61) | (568.76) | (1,350.51) |
| Other comprehensive income attributable to: | | | | | | |
| Equity holders of the Holding company | 1.91 | 0.89 | - | 2.80 | - | 2.04 |
| Non-controlling interest | 0.00 | 0.00 | - | 0.00 | - | 0.01 |
| Other comprehensive income for the year | 1.91 | 0.90 | - | 2.81 | - | 2.05 |
| Total comprehensive income attributable to: | | | | | | |
| Equity holders of the Holding company | (246.13) | (490.50) | (222.00) | (736.63) | (490.44) | (1,075.62) |
| Non-controlling interest | (4.79) | (36.39) | (34.30) | (41.17) | (78.32) | (272.84) |
| Total comprehensive income for the year | (250.92) | (526.88) | (256.31) | (777.81) | (568.76) | (1,348.47) |
| Paid-up Equity share capital (Face value Rs. 10/- per share) | 3,526.78 | 3,526.78 | 3,526.78 | 3,526.78 | 3,526.78 | 3,526.78 |
| Other Equity (excluding revaluation reserve) | | | | | | 2,405.25 |
| Earnings per equity share | | | | | | |
| Basic (in Rs) | (0.70) | (1.39) | (0.73) | (2.09) | (1.61) | (3.05) |
| Diluted (in Rs) | (0.70) | (1.39) | (0.73) | (2.09) | (1.61) | (3.05) |

Place: Bengaluru

Date: 11-11-2025

By the order of the Board of Directors
For Pharmaids Pharmaceuticals LimitedVenu Madhava Kaparthy
Whole Time Director
DIN : 00021699

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com


Notes to Accounts:

1. The Unaudited Consolidated Financial Results of Pharmaids(The Holding Company) and its subsidiaries (together referred to as Group) have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules thereafter and in accordance with the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. The Consolidated Financial Results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Holding Company at their respective Meetings held on November 11, 2025.
3. The group operates in a single segment of providing Contract Research and Manufacturing Services.
4. The figures for the previous periods have been regrouped / reclassified wherever considered necessary.
5. The holding company has disinvested its entire 66.5% partnership stake in Anugraha Chemicals, following shareholders' approval obtained through a Postal Ballot Notice in accordance with the Companies Act, 2013 and SEBI Listing Regulations. Therefore, Anugraha Chemicals is no longer a subsidiary, and its results are excluded from consolidation for the current quarter.

Place: Bengaluru

Date: 11-11-2025

**By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited**


Venu Madhava Kaparthy
Whole Time Director
DIN : 00021699



PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Consolidated Balance Sheet

All figures in Rs. Lacs unless otherwise specified

| Particulars | As at 30 Sep 2025 (Unaudited) | As at 31 March 2025 (Audited) |
|--|-------------------------------------|-------------------------------------|
| | | |
| ASSETS | | |
| Non-current assets | | |
| Property, plant and equipment | 2,067.27 | 4,104.16 |
| Capital work-in-progress | 325.48 | 453.01 |
| Right-of-use assets | 255.37 | 360.87 |
| Other Intangible Assets | - | 54.51 |
| Goodwill on Business purchase and consolidation | 3,141.66 | 3,141.66 |
| Financial assets | | |
| (i) Other financial assets | 585.78 | 690.12 |
| Deferred tax assets (net) | 1,024.36 | 1,050.34 |
| Other non-current assets | 26.27 | 32.00 |
| Total non-current assets | 7,426.20 | 9,886.68 |
| Current assets | | |
| Inventories | 399.96 | 1,218.41 |
| Financial assets | | |
| (i) Trade receivables | 869.52 | 312.83 |
| (ii) Cash and cash equivalents | 23.90 | 82.29 |
| (iii) Other financial assets | 817.08 | - |
| Other current assets | 307.17 | 485.05 |
| Total current assets | 2,417.64 | 2,098.58 |
| TOTAL ASSETS | 9,843.84 | 11,985.25 |
| EQUITY AND LIABILITIES | | |
| Equity | | |
| Equity share capital | 3,526.78 | 3,526.78 |
| Other equity | 1,665.14 | 2,405.25 |
| Equity attributable to the owners of the Company | 5,191.92 | 5,932.03 |
| Non-controlling Interest | (60.85) | (427.87) |
| Total equity | 5,131.07 | 5,504.16 |
| Liabilities | | |
| Non-current liabilities | | |
| Financial liabilities | | |
| (i) Borrowings | 1,290.97 | 3,018.35 |
| (ii) Lease liabilities | 206.17 | 293.52 |
| (iii) Other financial liabilities | 220.00 | 220.00 |
| Provisions | 14.04 | 77.78 |
| Total non-current liabilities | 1,731.17 | 3,609.65 |
| Current liabilities | | |
| Financial liabilities | | |
| (i) Borrowings | 451.90 | 506.30 |
| (ii) Lease liabilities | 64.11 | 79.31 |
| (iii) Trade payables | | |
| total outstanding dues of micro and small enterprises | 42.24 | 288.48 |
| total outstanding dues of creditors other than micro and small enterprises | 1,287.45 | 1,343.59 |
| (iv) Other financial liabilities | 690.17 | 489.87 |
| Provisions | 0.15 | 9.52 |
| Other current liabilities | 445.57 | 154.38 |
| Total Current Liabilities | 2,981.59 | 2,871.45 |
| TOTAL EQUITY AND LIABILITIES | 9,843.84 | 11,985.25 |

Place: Bengaluru
Date: 11-11-2025By the order of the Board of Directors
For Pharmaids Pharmaceuticals LimitedVenu Madhava Kaparthy
Whole Time Director
DIN: 00021699

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Consolidated Statement of Cash Flows

All figures in Rs. Lacs unless otherwise specified

| Particulars | Period ended 30 Sep 2025 (Unaudited) | Period ended 30 Sep 2024 (Unaudited) |
|---|--|--|
| | | |
| Cash flows from operating activities | | |
| Net Profit Before Tax | (1,079.05) | (786.46) |
| <i>Adjustments to reconcile profit before tax to net cash flows:</i> | | |
| Depreciation | 107.37 | 118.07 |
| Interest income | (21.65) | (1.95) |
| Finance Cost | 227.20 | 59.58 |
| Provision for gratuity | 6.32 | - |
| (Gain)/ Loss on sale of fixed asset | (316.25) | 14.58 |
| Loss/(Gain) on exit from subsidiary | 16.71 | - |
| Other Non cash adjustments | (47.01) | - |
| <i>Adjustments for changes in working capital:</i> | | |
| (Increase)/decrease in inventories | 601.90 | 122.93 |
| (Increase)/decrease in trade receivables | (693.85) | (51.54) |
| (Increase)/decrease in other financial assets | 104.68 | 179.96 |
| (Increase)/decrease in other current assets | 90.66 | (21.78) |
| Increase/(decrease) in trade payables | 72.53 | 71.69 |
| Increase/(decrease) in other financial liabilities | 240.61 | 75.98 |
| Increase/(decrease) in other provisions | (5.78) | (3.21) |
| Increase/(decrease) in other current liabilities | 322.98 | 259.63 |
| Cash generated from/(used in) operations | (372.63) | 37.49 |
| Income tax paid | - | (0.37) |
| Net cash flows generated from/(used in) operating activities (A) | (372.63) | 37.12 |
| Cash flows from investing activities | | |
| Purchase of property, plant and equipment incl. CWIP | (73.19) | (237.75) |
| Sale of property, plant and equipment | 1,955.94 | 16.25 |
| Interest on bank deposits | 52.80 | 0.20 |
| Investment in Fixed Deposit | (11.53) | - |
| Consideration received on Exit from subsidiary | 206.65 | - |
| Subsidy received | 37.11 | - |
| Loans given | (18.75) | (25.00) |
| Net cash flow generated from/(used in) investing activities (B) | 2,149.04 | (246.30) |
| Cash flow from Financing activities | | |
| Repayment of borrowing | (2,185.85) | - |
| Proceeds from borrowing | 458.58 | 264.77 |
| Repayment of partners' capital in subsidiary | - | - |
| Interest on loan | (67.21) | (40.46) |
| Repayment of lease liabilities | (40.32) | (36.37) |
| Net cash flow generated from/(used in) financing activities (C) | (1,834.80) | 187.95 |
| Net increase in cash and cash equivalents (A+B+C) | (58.39) | (21.24) |
| Cash and cash equivalents at the beginning of the year | 82.29 | 173.69 |
| Cash and cash equivalents at the end of the year | 23.90 | 152.46 |
| Cash and cash equivalents comprise | | |
| Cash on hand | 1.69 | 1.64 |
| Balances with banks in current & deposit accounts | 22.21 | 150.82 |
| Total cash and cash equivalents | 23.90 | 152.46 |

Place: Bengaluru

Date: 11-11-2025

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthu

Whole Time Director

DIN: 00021699

